CART123 cells; cyclophosphamide; fludarabine

BIOLOGICAL2 trials

Sponsors

University of Pennsylvania

Conditions

Acute Myeloid Leukemia, AdultAcute Myeloid Leukemia, PediatricAcute Myeloid Leukemia, RefractoryAcute Myeloid Leukemia, in Relapse

Phase 1

Lentivirally Redirected CD123 Autologous T Cells in AML

TerminatedNCT03766126

University of PennsylvaniaAcute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory

Start: 2018-12-06End: 2026-03-05Updated: 2026-07-10

CD123 Redirected T Cells for AML in Pediatric Subjects

TerminatedNCT04678336

University of PennsylvaniaAcute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory

Start: 2021-04-02End: 2025-05-09Updated: 2025-10-15

Related Papers

Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia

Blood2025-11-03

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

Blood2025-11-03

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Blood2024-11-051 citations

CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature

Blood2024-11-051 citations

Cytokine-mediated CAR T therapy resistance in AML.

2024-09-2754 citations

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Journal for ImmunoTherapy of Cancer2021-09-0167 citations